BioSpace News Archive

Delphinus Medical Technologies, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its SoftVue™ 3D Whole Breast Ultrasound Tomography System (SoftVue™) for use as an adjunct to digital mammography in the screening of asymptomatic women with dense breast tissue.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of new data at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) meeting, taking place virtually from October 19-21, 2021.

Windtree Therapeutics, Inc. today announced the results of a US physician survey and an assessment of worldwide total market value for cardiogenic shock.

Abeona Therapeutics Inc. today announced the appointment of Jon Voss as Vice President, Head of Quality.

Inhibrx, Inc. today announced interim results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency, or AATD.

Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host an Analyst & Investor Meeting on Monday, October 25, 2021 , in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting.

Nutriband Inc. announced that it has signed an exclusive manufacturing agreement with San Diego-based Diomics for its Diocheck™ technology, a simple way for individuals to monitor for the presence of antibodies to SARS-CoV-2 over an extended period of time.

Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced the appointment of Gene Mack as Chief Financial Officer effective immediately.

BridgeBio Pharma, Inc. is announcing meaningful progress in its KRAS cancer portfolio, new programs in gene therapy, and advancements in cardiorenal and early-stage Mendelian programs at its second annual R&D Day today.

Integral Molecular, a founding member of Philadelphia’s biotech community, celebrates its 20th anniversary as a leader in antibody discovery and virology.